Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma

Journal of the National Cancer Institute

Volumn 91, Issue 13, 1999, Pages 1154-1158

  Tannapfel, Andrea ^a   Wasner, Mark ^b   Krause, Karen ^b   Geissler, Felix ^b   Katalinic, Alexander ^b   Hauss, Johann ^b   Mössner, Joachim ^b   Engeland, Kurt ^b   Wittekind, Christian ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53; PROTEIN P73; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; COMORBIDITY; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SURVIVAL RATE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0033532910     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.13.1154     Document Type: Article

References (14)

1. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
2. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
3. Wittekind C. Hepatocellular carcinoma. In: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RV, Sobin LH, editors. Prognostic factors in cancer. Berlin (Germany): Springer-Verlag; 1995. p. 88-93.
4. Nomoto S, Haruki N, Kondo N, Konishi H, Takahashi T, Takahashi T, et al. Search for mutations and examination of allelic expression of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998;58:1380-3.
5. World Health Organization. Histological typing of tumours of the liver. 2nd ed. In: Ishak T, Ishak KG, Anthony PP, Sobin LH, editors. Berlin (Germany): Springer-Verlag; 1994.
6. International Union Against Cancer: TNM classification of malignant tumors. 5th ed. In: Sobin LH, Wittekind CH, editors. New York (NY): Wiley-Liss; 1997.
7. Tannapfel A, Hahn HA, Katalinic A, Fietkau R, Kuhn R, Wittekind CH. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996;77:164-71.
8. Roth J, Konig C, Wienzek S, Weigel S, Ristea S, Dobbelstein M. Inactivation of p53 but not p73 by adenovirus type 5E1B 55-kilodalton and E4 34-kilodalton oncoproteins. J Virol 1998;72:8510-6.
9. Bolognese F, Wasner M, Dohna CL, Gurtner A, Ronchi A, Muller H, et al. The cyclin B2 promoter depends on NF-γ, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene 1999;18:1845-53.
10. Mai M, Yokomizo A, Quian C, Yang P, Tindall DJ, Smith DI, Liu W. Activation of p73 silent allele in lung cancer. Cancer Res 1998; 58:2347-9.
11. Clurman B, Groudine M. Tumour-suppressor genes. Killer in search of a motive? [news]. Nature 1997;389:122-3.
12. Jost CA, Marin MC, Kaelin WG Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997;389:191-4.
13. Hui AM, Kanai Y, Sakamoto M, Tsuda H, Hirohashi S. Reduced p21 (WAF1/CIP1) expression and p53 mutation in HCC. Hepatology 1997;25:575-9.
14. Takahashi H, Ichimiya Y, Watanabe M, Furusato M, Wakui S, Yatani R, et al. Mutation, allotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998;58:2076-7.